NVCN - Neovasc Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9800
-0.1500 (-3.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 4.0700
Open 4.1600
Bid 3.9600 x 800
Ask 4.0000 x 800
Day's Range 3.9550 - 4.1900
52 Week Range 2.3400 - 45.8000
Volume 76,311
Avg. Volume 139,241
Market Cap 29.429M
Beta (3Y Monthly) 2.07
PE Ratio (TTM) N/A
EPS (TTM) -5.6380
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 1.88
Trade prices are not sourced from all markets
  • PR Newswire

    Neovasc Announces Changes to its Board of Directors

    VANCOUVER, Sept. 16, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Norman Radow, Managing Partner at Strul Medical Group ("Strul"), a leading investment firm that participated in Neovasc's $11.5 million financing, which was completed in May 2019, has been appointed to the Company's Board of Directors, effective immediately. Concurrently, Dr. Jane Hsiao has stepped down from Neovasc's Board in order to increase her focus on other business interests, effective immediately.

  • CNW Group

    Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  • CNW Group

    The European Society of Cardiology Includes Neovasc Reducer™ for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

    VANCOUVER , Sept. 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Neovasc Reducer™ (the "Reducer") for the treatment of patients suffering from refractory angina has been added to the European Society of Cardiology (ESC) Practice Guidelines. The ESC now recommends that the Reducer might be considered for the treatment of patients with angina, refractory to medical and interventional therapies. ESC Guidelines summarize and evaluate all available scientific evidence with the aim of assisting physicians in selecting the best evidence-based therapies and management strategies for an individual patient with a given condition.

  • CNW Group

    Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

    VANCOUVER , Aug. 22, 2019 /CNW/ - ("Neovasc" or the "Company") (NVCN)(NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days.

  • Nevro (NVRO) Catches Eye: Stock Jumps 6.3%
    Zacks

    Nevro (NVRO) Catches Eye: Stock Jumps 6.3%

    Nevro (NVRO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • CNW Group

    Neovasc Announces Second Quarter 2019 Financial Results

    VANCOUVER , Aug. 7, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, 2019 . "We have achieved tremendous progress in recent quarters," said Fred Colen , President and Chief Executive Officer of Neovasc.

  • PR Newswire

    Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference

    Presentation Scheduled for 11:30 am Eastern Time on August 8 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 5, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), ...

  • PR Newswire

    Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th

    Conference Call Scheduled for 4:30 pm Eastern Time on August 7 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 2, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: ...

  • PR Newswire

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

    VANCOUVER, July 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules"). Having regained compliance in respect of the minimum bid price deficiency and, as previously announced on June 25, 2019, the market value of listed securities deficiency, Neovasc has regained compliance in respect of all deficiency notices received from Nasdaq.

  • PR Newswire

    Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

    Pending U.S. Food and Drug Administration ("FDA") Humanitarian Use Device ("HUD") Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early ...

  • CNW Group

    Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

    Hydrodynamic performance testing is one of the core in vitro assessments required by the ISO 5840 series of standards for all prosthetic heart valves. A round-robin study carried out in 2005 in accordance with ISO 5840:2005 revealed significant variabilities in prosthetic heart valve hydrodynamic performance measurements among the participating laboratories.

  • CNW Group

    Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

    VANCOUVER , July 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Food and Drug Administration ("FDA") has provided guidance to the Company following its Sprint Discussion on June 26, 2019 , together with the Company's consultants and supporting U.S. cardiologists to review the clinical evidence collected to date for the Neovasc Reducer™ (the "Reducer"), to determine the most expedient pathway to potentially gaining regulatory approval in the United States and the quickest path to the U.S. market for these patients with an unmet need. In its guidance, the FDA has recommended that the Company consider potential alternate approaches such as: the Humanitarian Device Exemption ("HDE") pathway for class IV refractory angina patients and/or alternate clinical trial designs for a broader refractory angina patient population.

  • CNW Group

    Neovasc Announces Effective Date of Share Consolidation

    VANCOUVER , June 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 74,811,888 Common Shares to approximately 7,481,157 Common Shares.